Ajanta Pharma
- Market cap
- ₹ 41,234 Cr.
- P/E
- 38x
- P/B
- 9.03x
- 52-week range
- 2,382 – 3,796
- ROE
- 27%
- ROCE
- 35%
- Dividend yield
- 0.9%
- Debt / equity
- 0.06
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Ajanta Pharma Limited is an India-based specialty pharmaceutical company. It provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. It is focused on branded generic businesses across India, Asia, and Africa. It has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its business also consists of two verticals: the United States generics and the institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). Its cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin. Its subsidiaries include Ajanta Pharma (Mauritius) Limited, Ajanta Pharma USA Inc., Ajanta Pharma Philippines Inc., and Ajanta Pharma Nigeria Limited.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Ajanta Pharma against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)38 against a typical 34.3: pricier than most peers (1st = cheapest).125th of 220
- Sales growth+24.8% against a typical +15.6% from a year earlier.69th of 197
- Profit growth+31% against a typical +18.9% from a year earlier.69th of 160
- Share price, 3 months+2% against a typical −0.5%.86th of 200
- Size₹ 41,234.1 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).16th of 199
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
High safety
Rated AA+ by CARE- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CARE | CARE AA+ / CARE A1+ | Stable | 14 Aug 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 14 Aug 2026 | Reaffirmed | CARE AA+ / CARE A1+ | — | CARE | ₹ 72.5 Cr. | |
| 25 Aug 2025 | Reaffirmed | CARE AA+ / CARE A1+ | — | CARE | ₹ 72.5 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 30 Oct 2026Upcoming | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 30 Jul 2026 | Dividend | To consider dividend |
| 5 May 2026 | Financial Results | To consider and approve the financial results for the period ended March 31, 2026 |
| 30 Jan 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 3 Nov 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2025 and other business matters |
| 28 Jul 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2025 and other business matters |
| 30 Apr 2025 | Financial Results | To consider and approve the financial results for the period ended March 31, 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,028 | 1,105 | 1,054 | 1,145 | 1,187 | 1,146 | 1,170 | 1,303 | 1,354 | 1,375 | 1,422 | 1,626 |
| Expenses | 738 | 791 | 776 | 815 | 875 | 825 | 873 | 951 | 1,026 | 993 | 1,088 | 1,202 |
| Operating Profit | 291 | 314 | 278 | 330 | 311 | 321 | 297 | 351 | 328 | 382 | 333 | 424 |
| OPM % | 28% | 28% | 26% | 29% | 26% | 28% | 25% | 27% | 24% | 28% | 23% | 26% |
| Other Income | 21 | 14 | 36 | 26 | 19 | 30 | 18 | 26 | 59 | 25 | 61 | 71 |
| Interest | 2 | 2 | 2 | 1 | 6 | 8 | 6 | 5 | 3 | 5 | 2 | 3 |
| Depreciation | 34 | 34 | 34 | 34 | 34 | 36 | 40 | 41 | 43 | 44 | 45 | 44 |
| Profit before tax | 276 | 291 | 278 | 322 | 290 | 307 | 269 | 331 | 341 | 359 | 347 | 447 |
| Tax % | 29% | 28% | 27% | 24% | 25% | 24% | 16% | 23% | 24% | 24% | 23% | 25% |
| Net Profit | 195 | 210 | 203 | 246 | 216 | 233 | 225 | 255 | 260 | 274 | 267 | 334 |
| EPS in Rs | 15.24 | 16.39 | 15.82 | 19.68 | 17.33 | 18.64 | 18.03 | 20.44 | 20.83 | 21.91 | 21.35 | 26.75 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 12%
- 5 Years
- 14%
- 3 Years
- 13%
- TTM
- 20%
- 10 Years
- 10%
- 5 Years
- 12%
- 3 Years
- 24%
- TTM
- 22%
- 10 Years
- 11%
- 5 Years
- 20%
- 3 Years
- 27%
- TTM
- —
- 10 Years
- 23%
- 5 Years
- 23%
- 3 Years
- 25%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Ajanta Pharma | ₹ 3,465.00 | ₹ 41,234 Cr. | 38x | 9x | 27% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Madhusudan Bhagwandas Agrawal
- Executive Vice Chairman of the Board
- Arvind K. Agrawal
- Chief Financial Officer
- Gaurang C. Shah
- Vice President - Legal, Company Secretary
- Rajesh Mannalal Agrawal
- Joint Managing Director, Executive Director
- Yogesh Mannalal Agrawal
- Managing Director, Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.